Drug Profile
IG RD 002
Latest Information Update: 07 Oct 2009
Price :
$50
*
At a glance
- Originator Indigene Pharmaceuticals
- Class Antiallergics; Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Phase Unknown Asthma; Perennial allergic rhinitis
Most Recent Events
- 07 Oct 2009 Investigation in Perennial allergic rhinitis in Europe (unspecified route)